ArrowArtboardCreated with Sketch.Title ChevronCrossEye IconFacebook IconIcon FacebookGoogle Plus IconLayer 1InstagramCreated with Sketch.Linkedin IconIcon LinkedinShapeCreated with Sketch.Icon Mail ContactPath LayerIcon MailMenu BurgerIcon Opinion QuotePositive ArrowIcon PrintRSS IconIcon SearchSite TitleTitle ChevronTwitter IconIcon TwitterYoutube Icon
Health Technology

Sun Pharmaceutical Industries Ltd.

  • 623.70 INR
  • +0.40
  • +0.06%
  • India
    Aug 17, 2018
  • Ticker
    BOM(524715)
  • Prev. close
    623.30
  • Market cap (INR)
    1,495.46B
  • Market cap (USD)
    21,273.70M
  • Shares
    2,399.27M

Business Summary

Sun Pharmaceutical Industries Ltd. engages in manufacturing, developing, and marketing of pharmaceuticals products. It operates through the following geographical segments: India, the United States of America, Emerging Markets, and Rest of the World. It offers tablets, capsules, injectables, inhalers, ointments, creams, and liquids. The company was founded by Dilip Shantilal Shanghvi in 1982 and is headquartered in Mumbai, India.

Financial Highlights

Mar 2018 INRUSD
Revenue264,894.60M4,109.05M
Gross Profit142,648.30M2,212.76M
Operating income41,082.90M637.27M
Income before tax34,789.80M539.66M
Net income21,615.50M335.30M
EBITDA56,081.30M869.93M
Diluted EPS90.13
Dividends Per Share----
Total Assets643,028M9,859.11M
Total liabilities223,180.80M3,421.87M
Total equity381,005.60M5,841.70M
Operating cash flow----
Currency in INRCurrency in USD

Historical Data

 Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018
Revenue 160,043.90M 272,865M 281,086.10M 313,081.40M 264,894.60M
Gross Profit 102,872.40M 140,261.50M 149,951.40M 158,651.20M 142,648.30M
Operating income 69,559.90M 68,831.20M 75,140.60M 84,884.50M 41,082.90M
Income before tax 45,830.90M 64,029M 65,706.30M 90,478.70M 34,789.80M
Net income 31,433.90M 45,393.80M 45,457.10M 69,643.70M 21,615.50M
EBITDA 73,652.20M 80,778.40M 85,515.90M 97,532M 56,081.30M
Diluted EPS 15.20 18.90 18.90 29 9
Dividends Per Share 1.50 3 1 3.50 --
Total Assets 293,841M 494,235.80M 559,415.90M 619,117.90M 643,028M
Total liabilities 89,379.70M 209,343M 188,572.10M 214,674.70M 223,180.80M
Total equity 185,249.50M 256,231.90M 329,824.80M 366,396.70M 381,005.60M
Operating cash flow 41,341.80M 53,591.20M 67,726.30M 71,269.50M --
 Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018
Revenue 2,648.23M 4,462.70M 4,293.30M 4,668.88M 4,109.05M
Gross Profit 1,702.22M 2,293.97M 2,290.35M 2,365.91M 2,212.76M
Operating income 1,151.00M 1,125.73M 1,147.69M 1,265.85M 637.27M
Income before tax 758.35M 1,047.19M 1,003.59M 1,349.27M 539.66M
Net income 520.13M 742.41M 694.31M 1,038.57M 335.30M
EBITDA 1,218.71M 1,321.12M 1,306.16M 1,454.46M 869.93M
Diluted EPS 0.25 0.30 0.28 0.43 0.13
Dividends Per Share 0.02 0.04 0.01 0.05 --
Total Assets 4,920.10M 7,897.50M 8,447.51M 9,534.42M 9,859.11M
Total liabilities 1,496.58M 3,345.13M 2,847.55M 3,305.99M 3,421.87M
Total equity 3,101.83M 4,094.38M 4,980.55M 5,642.51M 5,841.70M
Operating cash flow 684.07M 876.48M 1,034.44M 1,062.81M --

Valuation Measures

Mar 2018
PER55.04
ROA3.42%
ROE5.78%
Operating margin15.50%
Profit margin8.16%

Key executives

  • Managing Director & Executive Director: Dilip Shantilal Shanghvi
  • Chief Financial Officer: C. S. Muralidharan
  • Compliance Officer, General Manager-Secretarial: Ashok I. Bhuta
  • Vice President & Global Head-Regulatory: Rajeev S. Mathur
  • Senior Vice President-Business Development: Kirti Wardhaman Ganorkar

Shareholders

  • SHANGHVI DILIP SHANTILAL (9.5%)
  • Viditi Investments Pvt Ltd. (8.3%)
  • Tejaskiran Pharmachem Industries Pvt Ltd. (8.1%)
  • Family Investment Pvt Ltd. (7.6%)
  • Quality Synthetic Industries Ltd. (7.6%)
  • Life Insurance Corp. of India (6.0%)
  • Virtuous Finance Ltd. (4.0%)
  • Virtuous Share Investments Pvt Ltd. (3.4%)
  • ICICI Prudential Asset Management Co. Ltd. (3.0%)
  • Aditya Medisales Ltd. (1.6%)

Contact Details

  • Website:http://www.sunpharma.com
  • Address: CTS No. 201 B/1, Sun House, Western Express Highway, Mumbai, 400063, India
  • Phone: +91.22.43244324

Related Companies

  • Sun Pharmaceuticals Morocco LLC Sarlau
  • Sun Pharmaceutical Industries (Australia) Pty Ltd.
  • Ocular Technologies SARL
  • Sun Pharmaceutical Industries Ltd. /7 Brands/
  • Sun Pharmaceutical Industries Ltd. /Bryan Ops/
  • GlaxoSmithKline Plc /Opiates Business/
  • Sun Global Canada Pty Ltd.
  • Sun Pharmaceutical Industries Europe BV
  • Aditya Acquisition Co. Ltd.
  • SPIL de Mexico SA de CV
  • Sun Pharma de Mexico SA de CV
  • Tamil Nadu Dadha Pharmaceuticals Ltd.
  • Pradeep Drug Co. Ltd.
  • Ranbaxy
  • Pharmalucence, Inc.
  • Alkaloida Chemical Co. Exclusive Group Ltd.
  • Sun Pharmaceutical Industries Key Employees Benefit Trust
  • Sun Pharmaceutical Industries, Inc.
  • Chattem Chemicals, Inc.
  • Generic Pharmaceutical Co.
  • Zenotech Laboratories Limited
  • Biosintez OAO
  • MJ Pharmaceuticals Ltd. /Manufacturing Business/
  • Phlox Pharmaceuticals Ltd.
  • Hindustan Antibiotics Ltd.
  • Gujarat Lyka Organics Ltd
  • ICN Magyarorszag Rt
  • Terapia SA
  • Caraco Acquisition Corp.
  • Taro Pharmaceutical Industries Ltd.

Competitors

  • Dr. Reddy's Laboratories Ltd.
  • Unichem Laboratories Limited
  • Perrigo Co. Plc
  • GlaxoSmithKline Pharmaceuticals Limited
  • Zentiva SA
  • Cytori Therapeutics, Inc.
  • Antares Pharma, Inc.
  • Antibiotice SA
  • ANI Pharmaceuticals, Inc.
  • Kala Pharmaceuticals, Inc.
  • Nicox SA
  • Biofrontera AG
  • Sienna Biopharmaceuticals, Inc.
  • Cumberland Pharmaceuticals Inc.
  • Lannett Company, Inc.
  • Chunghwa Chemical Synthesis & Biotech Co., Ltd. Class A
  • Curis, Inc.
  • TPI Enterprises Ltd.
  • Acura Pharmaceuticals, Inc.
  • Evolus, Inc.
  • Intec Pharma Ltd
  • Sol-Gel Technologies Ltd.
Last Updated on 17 Aug, 2018

You have {{numberReadArticles}} FREE ARTICLE{{numberReadArticles-plural}} left this month

Subscribe to get unlimited access to all articles.

Get unlimited access
NAR site on phone, device, tablet

You have {{numberReadArticles}} FREE ARTICLE{{numberReadArticles-plural}} left this month

Subscribe to get unlimited access to all articles.

3 months for $9

Get unlimited access
NAR site on phone, device, tablet

Your trial period has expired

You need a subscription to...

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers and subscribe

Your full access to the Nikkei Asian Review has expired

You need a subscription to:

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers
NAR on print phone, device, and tablet media